|
|
| Type |
Poster Presentation |
| Area |
Medicinal Chemistry |
| Room No. |
Event Hall |
| Time |
4월 19일 (목요일) 11:00~12:30 |
| Code |
MEDI.P-665 |
| Subject |
Proposition of Selective inhibitor for G1202R Mutant of Anaplastic Lymphoma Kinase(ALK) |
| Authors |
DONGKEUN HWANG
Ku-KIST, Korea university, Korea |
| Abstract |
Anaplastic lymphoma kinase (ALK) has been revolutionized by the treatment of crizotinib, a small-molecule inhibitor of ALK. Despite development of crizotinib, resistance to crizotinib gradually evolves through a variety of mechanisms, leading to relapse in the central nervous system(CNS). This result has motivated the research and development of second generation ALK inhibitors, including alectinib and ceritinib, that get over several mutations leading to resistance.1 However, G1202R and 1151Tins, the common mutations in ALK, are not suppressed by the second generation ALK inhibitors. For this reason, we have recently spent a lot of efforts on the development of G1202R mutant inhibitor.
|
| E-mail |
216344@kist.re.kr |
|
121st General Meeting of the KCS